Status:
COMPLETED
Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Pediatric Disorder
Pediatric Obesity
Eligibility:
All Genders
5-17 years
Brief Summary
Pediatric primary hypertension is increasingly common, occurring in 5-10% of normal-weight children and up to 25% of children with obesity. It is a risk factor for adult cardiovascular and renal disea...
Detailed Description
This proposal is to begin to elucidate the origins of pediatric primary hypertension and determine how it causes cardiac and renal disease. The primary hypothesis is than an altered renin-angiotensin ...
Eligibility Criteria
Inclusion
- Hypertension cohort: 5 to 17 years old with a new diagnosis of pediatric primary hypertension (systolic or diastolic blood pressure \>=95th percentile for age/sex/height or \>=130/80 mmHg.
- Normotensive controls with obesity: 5 to 17 years old with normal systolic and diastolic blood pressure (\<90th percentile for age/sex/height or \<120/80 mmHg) and BMI \>=85th percentile for age/sex.
- Normotensive controls: 5 to 17 years old with normal systolic and diastolic blood pressure (\<90th percentile for age/sex/height or \<120/80 mmHg).
Exclusion
- Secondary hypertension
- Confounding medical condition (e.g. diabetes mellitus, chronic kidney disease, heart disease, vascular disease, inflammatory or rheumatologic disease)
- Non-English and non-Spanish speaking
- Inability to complete assessments
Key Trial Info
Start Date :
December 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 26 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT03310684
Start Date
December 3 2018
End Date
April 26 2023
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States, 27157